<Superscript>137</Superscript>Cs transmission imaging and segmented attenuation corrections in a small animal PET scanner

Attenuation correction (AC) is required for accurate quantitative evaluation of small animal PET data. Our objective was to compare three AC methods in the small animal Clairvivo-PET scanner. The three AC methods involve applying attenuation coefficient maps generated by simulating a cylindrical map (SAC), segmenting the emission data (ESAC), and segmenting the transmission data (TSAC), imaged using a ¹³⁷Cs single-photon source. Investigation was carried out using a 65 mm uniform cylinder and an NEMA NU4 2008 mouse phantom, filled with water or tungsten liquid, to mimic bone. Evaluation was carried out using the difference of the segmented map volume from the known cylindrical phantom volume, the recovery of the radioactivity concentration, and the line profiles. The optimal transmission scan time for achieving accurate AC using TSAC was determined using 5, 10, 15, 20, and 25 min transmission scan time. The effects of scatter correction and reconstruction algorithms on ESAC were investigated. SAC showed the best performance but was unable to correct for different tissues and the scanner bed, and faced difficulty with correct positioning of the attenuation coefficient map. ESAC was affected by scatter correction and reconstruction algorithm, and may result in poor boundary delineation, and hence was unreliable. TSAC showed reasonable performance but required further optimization of the default segmentation setting. A minimum transmission scan time of 20 min is recommended for Clairvivo-PET using ¹³⁷Cs source to ensure that sufficient transmission counts are obtained to generate accurate attenuation coefficient map.     

不同衰减校正方法及无衰减校正对PET显像结果的影响

目的 探讨CT衰减校正(CTAC)、137Cs衰减校正(CsAC)及无衰减校正(NOAC)对PET图像质量和标准摄取值(SUV)的影响.方法 对Jaszczak模型及30例患者行PET/CT显像,均分别重建CTAC、CsAC和NOAC图像.30例患者中显像未见异常者9例,肺癌7例,肝癌4例,胰腺癌3例,肠癌7例.目测比较模型显像在CTAC、CsAC和NOAC时图像分辨率、均匀性的差异,计算CrAC、CsAC时模型显像均匀区各层面感兴趣区(ROI)的最大和最小百分比非均匀性(Nut),比较在CTAC和CsAC时平均SUV的差异.在图像上对患者正常软组织和骨组织、18F-脱氧葡萄糖(FDG)高摄取病灶以及高密度残留钡剂区勾画ROI,比较各ROI CTAC和CsAC的平均SUV差异,以及CTAC、CsAC和NOAC的图像差异.采用SPSS 12.0软件,2组数据间比较行配对t检验.结果 目测比较模型显像的图像分辨率,在CTAC和CsAC时无明显差异,NOAC图像中心区域的分辨率明显下降;CTAC和CsAC图像均匀性明显优于NOAC.CTAC图像Nut为(23±2)%(最大)、(19±1)%(最小),均匀性优于CsAC[Nut为(29±3)%(最大)、(23±2)%(最小)],两者平均SUV差异无统计学意义(0.9±0.1和1.0±0.1;t=0.367,P=0.719).患者正常软组织及FDG高摄取病灶CTAC和CsAC时的平均SUV差异无统计学意义(0.71±0.20和0.75±0.23,t=-2.159,P=0.054;5.50±4.80和5.70±5.00,t=-2.032,P=0.0.54);在正常骨组织及高密度残留钡剂区中,CTAC的平均SUV明显高于CsAC(1.37±0.29和1.18±0.36,t=7.960,P=0.001;1.82±0.62和0.92±0.20,t=3.451,P=0.018).正常软组织、骨组织及FDG高摄取病灶的CTAC和CsAC图像差异不影响诊断效果.高密度残留钡剂区在CTAC图像上表现为FDG高摄取伪影,而CsAC及NOAC图像上为正常摄取.结论 CTAC和CsAC的图像分辨率无明显差异,CTAC的图像均匀性优于CsAC,两者图像质量均明显优于NOAC;CTAC对高密度物质的SUV可明显高估,且可出现FDG高摄取伪影.     

Correction for oral contrast artifacts in CT attenuation-corrected PET images obtained by combined PET/CT.

Recent studies have shown increased artifacts in CT attenuation-corrected (CTAC) PET images acquired with oral contrast agents because of misclassification of contrast as bone. We have developed an algorithm, segmented contrast correction (SCC), to properly transform CT numbers in the contrast regions from CT energies (40-140 keV) to PET energy at 511 keV. METHODS: A bilinear transformation, equivalent to that supplied by the PET/CT scanner manufacturer, for the conversion of linear attenuation coefficients of normal tissues from CT to PET energies was optimized for BaSO(4) contrast agent. This transformation was validated by comparison with the linear attenuation coefficients measured for BaSO(4) at concentrations ranging from 0% to 80% at 511 keV for PET transmission images acquired with (68)Ge rod sources. In the CT images, the contrast regions were contoured to exclude bony structures and then segmented on the basis of a minimum threshold CT number (300 Hounsfield units). The CT number in each pixel identified with contrast was transformed into the corresponding effective bone CT number to produce the correct attenuation coefficient when the data were translated by the manufacturer software into PET energy during the process of CT attenuation correction. CT images were then used for attenuation correction of PET emission data. The algorithm was validated with a phantom in which a lesion was simulated within a volume of BaSO(4) contrast and in the presence of a human vertebral bony structure. Regions of interest in the lesion, bone, and contrast on emission PET images reconstructed with and without the SCC algorithm were analyzed. The results were compared with those for images obtained with (68)Ge-based transmission attenuation-corrected PET. RESULTS: The SCC algorithm was able to correct for contrast artifacts in CTAC PET images. In the phantom studies, the use of SCC resulted in an approximate 32% reduction in the apparent activity concentration in the lesion compared with data obtained from PET images without SCC and a <7.6% reduction compared with data obtained from (68)Ge-based attenuation-corrected PET images. In one clinical study, maximum standardized uptake value (SUV(max)) measurements for the lesion, bladder, and bowel were, respectively, 14.52, 13.63, and 13.34 g/mL in CTAC PET images, 59.45, 26.71, and 37.22 g/mL in (68)Ge-based attenuation-corrected PET images, and 11.05, 6.66, and 6.33 g/mL in CTAC PET images with SCC. CONCLUSION: Correction of oral contrast artifacts in PET images obtained by combined PET/CT yielded more accurate quantitation of the lesion and other, normal structures. The algorithm was tested in a clinical case, in which SUV(max) measurements showed discrepancies of 2%, 1.3%, and 5% between (68)Ge-based attenuation-corrected PET images and CTAC PET images with SCC for the lesion, bladder, and bowel, respectively. These values correspond to 6.5%, 62%, and 66% differences between CTAC-based measurements and (68)Ge-based ones.     

Clinical implications of different image reconstruction parameters for interpretation of whole-body PET studies in cancer patients.

The standardized uptake value (SUV) is the most commonly used parameter to quantify the intensity of radiotracer uptake in tumors. Previous studies suggested that measurements of (18)F-FDG accumulation in tissue might be affected by the image reconstruction method, but the clinical relevance of these findings has not been assessed. METHODS: Phantom studies were performed and clinical whole-body (18)F-FDG PET images of 85 cancer patients were analyzed. All images were reconstructed using either filtered backprojection (FBP) with measured attenuation correction (MAC) or iterative reconstruction (IR) with segmented attenuation correction (SAC). In a subset of 15 patients, images were reconstructed using all 4 combinations of IR+SAC, IR+MAC, FBP+SAC, and FBP+MAC. For phantom studies, a sphere containing (18)F-FDG was placed in a water-filled cylinder and the activity concentration of that sphere was measured in FBP and IR reconstructed images using all 4 combinations. Clinical studies were displayed simultaneously and identical regions of interest (ROIs, 50 pixels) were placed in liver, urinary bladder, and tumor tissue in both image sets. SUV max (maximal counts per pixel in ROI) and SUV avg (average counts per pixel) were measured. RESULTS: In phantom studies, measurements from FBP images underestimated the true activity concentration to a greater degree than those from IR images (20% vs. 5% underestimation). In patient studies, SUV derived from FBP images were consistently lower than those from IR images in both normal and tumor tissue: Tumor SUV max with IR+SAC was 9.6 +/- 4.5, with IR+MAC it was 7.7 +/- 3.5, with FBP+MAC it was 6.9 +/- 3.0, and with FBP+SAC it was 8.6 +/- 4.1 (all P < 0.01 vs. IR+SAC). Compared with IR+SAC, SUV from FBP+MAC images were 25%-30% lower. Similar discrepancies were noted for liver and bladder. Discrepancies between measurements became more apparent with increasing (18)F-FDG concentration in tissue. CONCLUSION: SUV measurements in whole-body PET studies are affected by the applied methods for both image reconstruction and attenuation correction. This should be considered when serial PET studies are done in cancer patients. Moreover, if SUV is used for tissue characterization, different cutoff values should be applied, depending on the chosen method for image reconstruction and attenuation correction.     

不同浓度泛影葡胺及不同CT扫描条件对PET/CT图像质量和标准摄取值的影响

目的 探讨不同浓度泛影葡胺及不同CT扫描条件对PET/CT图像质量和标准摄取值的影响.材料与方法 分别将2％、5％、10％、15％、30％的泛影葡胺溶液置入一圆桶模型中进行PET/CT显像,同时采用CT及37Cs两种衰减方法进行校正.比较不同管电压(90kV、120kV、140kV) CT扫描条件下各浓度泛影葡胺充盈区CT衰减校正(CTAC)和137Cs衰减校正(CsAC)的标准摄取值差异及图像差异.结果 不同管电压CT扫描条件下的CT衰减校正的标准摄取值均随泛影葡胺浓度增加而增加(r=0.977、0.979、0.985,P＜0.01),而137Cs衰减校正的标准摄取值则与泛影葡胺浓度无明显相关性(r=0.386,P＞ 0.05);在本底区、清水充盈区及浓度为2％的泛影葡胺充盈区,各CT衰减校正和137Cs衰减校正的标准摄取值间差异无统计学意义(F=1.222、0.912、0.721,P＞0.05);在浓度为5％、10％、15％、30％的泛影葡胺充盈区,CT衰减校正的标准摄取值明显高于137Cs衰减校正值(F=82.571、348.211、569.630、992.746,P＜0.01),管电压越高CT衰减校正的标准摄取值越小.在浓度为15％、30％的泛影葡胺充盈区,不同管电压CT扫描条件下的图像均出现18F-FDG高摄取伪影,以140kV下的图像“热区”范围及强度最小,而相同区域的137Cs衰减校正及无衰减校正图像均表现为圆形“冷区”.结论 高浓度(≥5％)的泛影葡胺可使PET图像出现高摄取伪影或标准摄取值的高估,增加CT扫描管电压值可以减轻图像伪影并减小标准摄取值的误差.     

Comparison of activity expression between PET using 68Ge-68Ga line source attenuation correction and PET-CT using CT attenuation correction: impact on emission images

OBJECTIVES: CT data can be used for both anatomical image and attenuation correction (CTAC) of PET data in PET-CT scanners. The CTAC method is useful for attenuation correction, because the CT scan time is much shorter than the external radionuclide (e.g., (68)Ge) transmission scan time. However, the energy of the X-rays from CT is not monoenergetic and is much lower than that of the external radionuclide source. In this study, we evaluated the differences between emission PET images reconstructed with CT-based and (68)Ge-based attenuation correction. METHODS: CT scans and (68)Ge-Transmission scans were acquired and used for attenuation correction (CTAC, MAC, and SAC). The PET emission scan time was 4 min. CT scans were acquired at 10, 20, 40, 80, and 160 mA. (68)Ge-Transmission scans were acquired at 1, 3, 5, 10, 20, 40, 60, and 300 min. The attenuation-corrected emission image using MAC on a 300 min transmission scan was defined as the reference image. Seven cylinders (30 mm diameter) were filled with (18)F-FDG placed in a heart-liver phantom with simulated pulmonary mass lesions. The PET value [counts/cc] was measured in circular regions of interest (ROI) over the cylindrical mass lesion. Averages [counts/cc], coefficients of variation [C.V.(%)], and ratios of difference [%Diff] from the reference value were calculated for all conditions. RESULTS: In the CT-Transmission, analysis of variance revealed no significant effect of CT current on the average and the C.V. In the (68)Ge-Transmission, the average and the C.V. changed in dependence on the acquisition time. All %Diff using CT-Transmission were small. It was shown that CT-Transmission is more appropriate than (68)Ge-Transmission.     

Respiratory motion artifacts on PET emission images obtained using CT attenuation correction on PET-CT

PET-CT scanners allow generation of transmission maps from CT. The use of CT attenuation correction (CTAC) instead of germanium-68 attenuation correction (Ge AC) might be expected to cause artifacts on reconstructed emission images if differences in respiratory status exist between the two methods of attenuation correction. The aim of this study was to evaluate for possible respiratory motion artifacts (RMA) in PET images attenuation corrected with CT from PET-CT in clinical patients. PET-CT scans were performed using a Discovery LS PET-CT system in 50 consecutive patients (23 males, 27 females; mean age 58.2 years) with known or suspected malignancy. Both CTAC and Ge AC transmission data obtained during free tidal breathing were used to correct PET emission images. Cold artifacts at the interface of the lungs and diaphragm, believed to be due to respiratory motion (RMA), that were seen on CTAC images but not on the Ge AC images were evaluated qualitatively on a four-point scale (0, no artifact; 1, mild artifact; 2, moderate artifact; 3, severe artifact). RMA was also measured for height. Curvilinear cold artifacts paralleling the dome of the diaphragm at the lung/diaphragm interface were noted on 84% of PET-CT image acquisitions and were not seen on the (68)Ge-corrected images; however, these artifacts were infrequently severe. In conclusion, RMA of varying magnitude were noted in most of our patients as a curvilinear cold area at the lung/diaphragm interface, but were not diagnostically problematic in these patients.     

Computed tomography-based attenuation correction in neurological positron emission tomography: evaluation of the effect of the X-ray tube voltage on quantitative analysis

BACKGROUND: The advent of dual-modality positron emission tomography/computed tomography (PET/CT) imaging has revolutionized the practice of clinical oncology by improving lesion localization and facilitating treatment planning for radiation therapy. In addition, the use of CT images for CT-based attenuation correction (CTAC) allows the overall scanning time to be decreased and a noise-free attenuation map (micromap) to be created. The most common procedure requires a piecewise linear calibration curve acquired under standard imaging conditions to convert the patient's CT image from low effective CT energy into an attenuation map at 511 keV. AIM: To evaluate the effect of the tube voltage on the accuracy of CTAC. METHODS: As different tube voltages are employed in current PET/CT scanning protocols, depending on the size of the patient and the region under study, the impact of using a single calibration curve on the accuracy of CTAC for images acquired at different tube voltages was investigated through quantitative analysis of the created micromaps, generated attenuation correction factors and reconstructed neurological PET data using anthropomorphic experimental phantom and clinical studies. RESULTS: For CT images acquired at 80 and 140 kVp, average relative differences of -2.9% and 0.7%, respectively, from the images acquired at 120 kVp were observed for the absolute activity concentrations in five regions of the anthropomorphic striatal phantom when CT images were converted using a single calibration curve derived at 120 kVp. Likewise, average relative differences of 1.9% and -0.6% were observed when CT images were acquired at 120 kVp and CTAC used calibration curves derived at 80 and 140 kVp, respectively. CONCLUSION: The use of a single calibration curve acquired under standard imaging conditions does not affect, to a visible or measurable extent, neurological PET images reconstructed using CTAC when CT images are acquired in different conditions.     

The effect of metal artefact reduction on CT-based attenuation correction for PET imaging in the vicinity of metallic hip implants: a phantom study

Background

To determine if metal artefact reduction (MAR) combined with a priori knowledge of prosthesis material composition can be applied to obtain CT-based attenuation maps with sufficient accuracy for quantitative assessment of ¹⁸F-fluorodeoxyglucose uptake in lesions near metallic prostheses.

Methods

A custom hip prosthesis phantom with a lesion-sized cavity filled with 0.2 ml ¹⁸F-FDG solution having an activity of 3.367 MBq adjacent to a prosthesis bore was imaged twice with a chrome–cobalt steel hip prosthesis and a plastic replica, respectively. Scanning was performed on a clinical hybrid PET/CT system equipped with an additional external ¹³⁷Cs transmission source. PET emission images were reconstructed from both phantom configurations with CT-based attenuation correction (CTAC) and with CT-based attenuation correction using MAR (MARCTAC). To compare results with the attenuation-correction method extant prior to the advent of PET/CT, we also carried out attenuation correction with ¹³⁷Cs transmission-based attenuation correction (TXAC). CTAC and MARCTAC images were scaled to attenuation coefficients at 511 keV using a trilinear function that mapped the highest CT values to the prosthesis alloy attenuation coefficient. Accuracy and spatial distribution of the lesion activity was compared between the three reconstruction schemes.

Results

Compared to the reference activity of 3.37 MBq, the estimated activity quantified from the PET image corrected by TXAC was 3.41 MBq. The activity estimated from PET images corrected by MARCTAC was similar in accuracy at 3.32 MBq. CTAC corrected PET images resulted in nearly 40 % overestimation of lesion activity at 4.70 MBq. Comparison of PET images obtained with the plastic and metal prostheses in place showed that CTAC resulted in a marked distortion of the ¹⁸F-FDG distribution within the lesion, whereas application of MARCTAC and TXAC resulted in lesion distributions similar to those observed with the plastic replica.

Conclusions

MAR combined with a trilinear CT number mapping for PET attenuation correction resulted in estimates of lesion activity comparable in accuracy to that obtained with ¹³⁷Cs transmission-based attenuation correction, and far superior to estimates made without attenuation correction or with a standard CT attenuation map. The ability to use CT images for attenuation correction is a potentially important development because it obviates the need for a ¹³⁷Cs transmission source, which entails extra scan time, logistical complexity and expense.     

<Superscript>18</Superscript>FDG PET scanning of benign and malignant musculoskeletal lesions

OBJECTIVE: To describe the technique, applications and advantages of (18)FDG PET scanning in detection, analysis and management of musculoskeletal lesions. DESIGN AND PATIENTS: Forty-five patients (19 males,26 females) aged 9 to 81 years had radiographs, routine radionuclide scans, CT and/or MRI of clinically suspected active benign or malignant musculoskeletal lesions. (18)FDG scans with a Siemens ECAT EXACT 921 dedicated PET unit (Knoxville, Tenn.) and FWH=6 mm images acquired as a 5-6 bed examination (6 min emission and 4 min transmission) used OSEM iterative reconstruction with segmented transmission attenuation correction and a Gaussian filter (cutoff 6.7 mm). Region of interest (ROI) 3x3 pixel image analysis based on transverse whole body images (slice thickness 3.37 mm) generated Maximum Standard Uptake Values (Max SUV) with a cutoff of 2.0 used to distinguish benign and malignant lesions. RESULTS: Thirty-nine studies were available for SUV ROI analysis. Overall sensitivity for differentiating malignant from benign osseous and non-osseous lesions was 91.7% (22/24), overall specificity was 100% (11/11) with an accuracy of 91.7%. All aggressive lesions had a Max SUV >2.0. Data separating benign from malignant lesions and aggressive from benign lesions were statistically significant ( P<0.001) in both categories. There was no statistically significant difference in distinguishing aggressive from malignant lesions ( P, ns). CONCLUSION: (18)FDG PET contributes unique information regarding metabolism of musculoskeletal lesions. By supplying a physiologic basis for more informed treatment and management, it influences prognosis and survival. Moreover, since residual, recurrent or metastatic tumors can be simultaneously documented on a single whole body scan, PET may theoretically prove to be cost-effective.     

Fundamental evaluation of segmented attenuation correction method for clinical FDG-PET studies: simulation of pulmonary mass lesions in phantom studies

OBJECTIVE: Both the segmented attenuation correction (SAC) method and post-injection transmission scanning are useful and widespread in clinical whole-body FDG-PET studies. The SAC method usually accomplishes smoothing of the transmission data. This calculation segments a micro -map into three degrees (lung, soft tissue, and bone) of attenuation coefficient. This method is used to reduce transmission scan time without deteriorating the quality of PET images. However, the SAC method has a tendency to underestimate the attenuation coefficient, resulting lower detectability for lung field mass lesions. We therefore evaluated the quantitative accuracy of the SAC method using transmission scanning and emission scanning data in a phantom study. METHODS: A dedicated 3D PET scanner, the Siemens ECAT EXACT HR+, was used to scan images of two types of phantoms, a spherical phantom (Japan Radioisotope Association phantom) and a cylindrical phantom (20 cm in diameter). We evaluated differences between transmission images ( micro -map) of the SAC method and measured attenuation correction (MAC) method, these two kinds of attenuation-corrected emission data (emission + SAC method, emission + MAC method), and emission data only (without attenuation correction). RESULTS: In the micro -map, recovery coefficient (RC) values at 10 mm in diameter were 0.27 and 0.00 in the MAC and SAC methods, respectively, in the spherical hot area. For the emission data, the emission + SAC method and emission + MAC method showed almost the same RC values for all sizes of hot area diameter. The SAC method, however, resulted in 20% underestimation for all sizes of hot area diameter as compared with the MAC method. CONCLUSION: In pulmonary mass lesions, it is necessary to correct for the partial volume effect in quantitative PET measurement. However, from our data, the SAC method is not appropriate for partial volume effect correction.     

Cause and magnitude of the error induced by oral CT contrast agent in CT-based attenuation correction of PET emission studies.

CT images represent essentially noiseless maps of photon attenuation at a range of 40-140 keV. Current dual-modality PET/CT scanners transform them into attenuation coefficients at 511 keV and use these for PET attenuation correction. The proportional scaling algorithms hereby used account for the different properties of soft tissue and bone but are not prepared to handle material with other attenuation characteristics, such as oral CT contrast agents. As a consequence, CT-based attenuation correction in the presence of an oral contrast agent results in erroneous PET standardized uptake values (SUVs). The present study assessed these errors with phantom measurements and patient data. METHODS: Two oral CT contrast agents were imaged at 3 different concentrations in dual-modality CT and PET transmission studies to investigate their attenuation properties. The SUV error due to the presence of contrast agent in CT-based attenuation correction was estimated in 10 patients with gastrointestinal tumors as follows. The PET data were attenuation corrected on the basis of the original contrast-enhanced CT images, resulting in PET images with distorted SUVs. A second reconstruction used modified CT images wherein the CT numbers representing contrast agent had been replaced by CT values producing approximately the right PET attenuation coefficients. These CT values had been derived from the data of 10 patients imaged without a CT contrast agent. The SUV error, defined as the difference between both sets of SUV images, was evaluated in regions with oral CT contrast agent, in tumor, and in reference tissue. RESULTS: The oral CT contrast agents studied increased the attenuation for 511-keV photons minimally, even at the highest concentrations found in the patients. For a CT value of 500 Hounsfield units, the proportional scaling algorithm therefore overestimated the PET attenuation coefficient by 26.2%. The resulting SUV error in the patient studies was highest in regions containing CT contrast agent (4.4% +/- 2.8%; maximum, 11.3%), whereas 1.2% +/- 1.1% (maximum, 4.1%) was found in tumors, and 0.6% +/- 0.7% was found in the reference. CONCLUSION: The use of oral contrast agents in CT has only a small effect on the SUV, and this small effect does not appear to be medically significant.     

PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients

Purpose If the CT scan of a combined PET/CT study is performed as a full diagnostic quality CT scan including intravenous (IV) contrast agent, the quality of the joint PET/CT procedure is improved and a separate diagnostic CT scan can be avoided. CT with IV contrast can be used for PET attenuation correction, but this may result in a bias in the attenuation factors. The clinical significance of this bias has not been established. Our aim was to perform a prospective clinical study where each patient had CT performed with and without IV contrast agent to establish whether PET/CT with IV contrast can be used for PET attenuation without reducing the clinical value of the PET scan.Methods A uniform phantom study was used to document that the PET acquisition itself is not significantly influenced by the presence of IV contrast medium. Then, 19 patients referred to PET/CT with IV contrast underwent CT scans without, and then with contrast agent, followed by an ¹⁸F-fluorodeoxyglucose whole-body PET scan. The CT examinations were performed with identical parameters on a GE Discovery LS scanner. The PET data were reconstructed with attenuation correction based on the two CT data sets. A global comparison of standard uptake value (SUV) was performed, and SUVs in tumour, in non-tumour tissue and in the subclavian vein were calculated. Clinical evaluation of the number and location of lesions on all PET/CT scans was performed twice, blinded and in a different random order, by two independent nuclear medicine specialists.Results In all patients, the measured global SUV of PET images based on CT with IV contrast agent was higher than the global activity using non-contrast correction. The overall increase in the mean SUV (for two different conversion tables tested) was 4.5±2.3% and 1.6±0.5%, respectively. In 11/19 patients, focal uptake was identified corresponding to malignant tumours. Eight out of 11 tumours showed an increased SUV_max (2.9±3.1%) on the PET images reconstructed using IV contrast. The clinical evaluation performed by the two specialists comparing contrast and non-contrast CT attenuated PET images showed weighted kappa values of 0.92 (doctor A) and 0.82 (doctor B). No contrast-introduced artefacts were found.Conclusion This study demonstrates that CT scans with IV contrast agent can be used for attenuation correction of the PET data in combined modality PET/CT scanning, without changing the clinical diagnostic interpretation.     

Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction,resolution and ROI definition parameters

Purpose Standardised uptake values (SUVs) depend on acquisition, reconstruction and region of interest (ROI) parameters. SUV quantification in multi-centre trials therefore requires standardisation of acquisition and analysis protocols. However, standardisation is difficult owing to the use of different scanners, image reconstruction and data analysis software. In this study we evaluated whether SUVs, obtained at three different institutes, may be directly compared after calibration and correction for inter-institute differences. Methods First, an anthropomorphic thorax phantom containing variously sized spheres and activities, simulating tumours, was scanned and processed in each institute to evaluate differences in scanner calibration. Secondly, effects of image reconstruction and ROI method on recovery coefficients were studied. Next, SUVs were derived for tumours in 23 subjects. Of these 23 patients, four and ten were scanned in two institutes on an HR+ PET scanner and nine were scanned in one institute on an ECAT EXACT PET scanner. All phantom and clinical data were reconstructed using iterative reconstruction with various iterations, with both measured (MAC) and segmented attenuation correction (SAC) and at various image resolutions. Activity concentrations (AC) or SUVs were derived using various ROI isocontours. Results Phantom data revealed differences in SUV quantification of up to 30%. After application-specific calibration, recovery coefficients obtained in each institute were equal to within 15%. Varying the ROI isocontour value resulted in a predictable change in SUV (or AC) for both phantom and clinical data. Variation of image resolution resulted in a predictable change in SUV quantification for large spheres/tumours (>5 cc) only. For smaller tumours (<2 cc), differences of up to 40% were found between high (7 mm) and low (10 mm) resolution images. Similar differences occurred when data were reconstructed with a small number of iterations. Finally, no significant differences between MAC and SAC reconstructed data were observed, except for tumours near the diaphragm. Conclusion Standardisation of acquisition, reconstruction and ROI methods is preferred for SUV quantification in multi-centre trials. Small unavoidable differences in methodology can be accommodated by performing a phantom study to assess inter-institute correction factors.     

Assessment of errors caused by X-ray scatter and use of contrast medium when using CT-based attenuation correction in PET

Purpose Quantitative image reconstruction in positron emission tomography (PET) requires an accurate attenuation map of the object under study for the purpose of attenuation correction. Current dual-modality PET/CT systems offer significant advantages over stand-alone PET, including decreased overall scanning time and increased accuracy in lesion localisation and detectability. However, the contamination of CT data with scattered radiation and misclassification of contrast medium with high-density bone in CT-based attenuation correction (CTAC) are known to generate artefacts in the attenuation map and thus the resulting PET images. The purpose of this work was to quantitatively measure the impact of scattered radiation and contrast medium on the accuracy of CTAC.Methods Our recently developed MCNP4C-based Monte Carlo X-ray CT simulator for modelling both fan- and cone-beam CT scanners and the Eidolon dedicated 3D PET Monte Carlo simulator were used to generate realigned PET/CT data sets. The impact of X-ray scattered radiation on the accuracy of CTAC was investigated through simulation of a uniform cylindrical water phantom for both a commercial fan-beam multi-slice and a prototype cone-beam flat panel detector-based CT scanner. The influence of contrast medium was studied by simulation of a cylindrical phantom containing different concentrations of contrast medium. Moreover, an experimental study using an anthropomorphic striatal phantom was conducted for quantitative evaluation of errors arising from the presence of contrast medium by calculating the apparent recovery coefficient (ARC) in the presence of different concentrations of contrast medium.Results The analysis of attenuation correction factors (ACFs) for the simulated cylindrical water phantom in both fan- and cone-beam CT scanners showed that the contamination of CT data with scattered radiation in the absence of scatter removal causes underestimation of the true ACFs, namely by 7.3% and 28.2% in the centre for the two geometries, respectively. The ARC was 190.7% for a cylindrical volume of interest located in the main chamber of the striatal phantom containing contrast medium corresponding to 2,000 Hounsfield units, whereas the ARC was overestimated by less than 5% for the main chamber and by ∼2% for the left/right putamen and caudate nucleus compared with the absence of contrast medium.Conclusion Without X-ray scatter compensation, the visual artefacts and quantitative errors in flat panel detector-based cone-beam geometry are substantial and propagate cupping artefacts to PET images during CTAC. Likewise, contrast-enhanced CT images may create considerable artefacts during CTAC in regions containing high concentrations of contrast medium.     

9:15-9:30. A Clinical Evaluation of Segmented Attenuation Correction

Segmented attenuation correction (SAC) has been introduced as a method of reducing transmission scan times without degrading the quality of PET images. Presented are the results of a clinical evaluation of a SAC algorithm implemented on the GE Advance PET system. FDG whole body patient emission scans of eight minute duration were acquired. Dynamic transmission (Tx) scans of 5 frames and 6 minute total duration were acquired and rebinned into Tx scans of 2, 3, 4, 5 and 6 minute duration. Images (I) were generated using iterative reconstruction with measured attenuation correction (MAC) or SAC for all Tx scans-denoted as I(Tx6MAC), I(Tx6SAC), etc. Anthropomorphic phantom data was also acquired and reconstructed using the same methodology. Images were evaluated quantitatively using the normalized mean square error (NMSE) of different regions and the variance and bias of liver activity. I(Tx6MAC) served as the reference. A blinded observer ranked image quality. The NMSE increased as the Tx duration decreased; for patient images the NMSE was typically 20% and 40% greater for I(Tx3SAC) and I(Tx2SAC) than I(Tx6SAC) respectively. The NMSE of the MAC images increased much more rapidly as the Tx duration decreased. Similar trends were found for the variance in the liver. Bias in liver activity of the SAC images was approximately -8% for large patients. The observer consistently preferred SAC images over MAC images. SAC images demonstrated improved boundary delineation and reduced noise in areas of homogeneous high activity background. Areas of discordance were projected into areas of large difference between Tx and segmented Tx sinograms. This study has validated the use of SAC with short Tx scans. Images reconstructed with Tx scans of 3 minutes were not compromised with noise or severe artifacts.     

Quantifying the effect of IV contrast media on integrated PET/CT: clinical evaluation

OBJECTIVES: The use of IV contrast media in PET/CT can result in an overestimation of PET attenuation factors that potentially can affect interpretation. The objective of this study was to quantify the effect of IV contrast media in PET/CT and assess its impact on patients with intrathoracic malignancies. MATERIALS AND METHODS: Nine patients had CTs performed with and without IV contrast media followed by (18)F-FDG PET. PET images were reconstructed using contrast-enhanced and unenhanced CT. To quantify the effect of contrast media on standardized uptake values (SUV), similar regions of interest (ROIs) were drawn on the subclavian vein, heart, liver, spleen, and site of malignancy on both CT and corresponding reconstructed PET images, and the mean and maximum values were compared. In addition, two physicians blinded to the imaging parameters that were used evaluated the reconstructed PET images to assess whether IV contrast media had an effect on clinical interpretation. RESULTS: For all patient studies, the subclavian vein region on the ipsilateral side of contrast media administration had the highest increase in CT numbers with a corresponding average SUV(max) increase of 27.1%. Similarly, ROIs of the heart and at the site of malignancy showed an increase in the maximum attenuation value with a corresponding average SUV(max) increase of 16.7% and 8.4%, respectively. Other locations had relatively small attenuation value differences with a correspondingly negligible SUV variation. CONCLUSION: Although there is a significant increase in SUV in regions of high-contrast concentration when contrast-enhanced CT is used for attenuation correction, this increase is clinically insignificant. Accordingly, in PET/CT, IV contrast-enhanced CT can be used in combination with the PET to evaluate patients with cancer.     

Correction of oral contrast artifacts in CT-based attenuation correction of PET images using an automated segmentation algorithm

Purpose  Oral contrast is usually administered in most X-ray computed tomography (CT) examinations of the abdomen and the pelvis as it allows more accurate identification of the bowel and facilitates the interpretation of abdominal and pelvic CT studies. However, the misclassification of contrast medium with high-density bone in CT-based attenuation correction (CTAC) is known to generate artifacts in the attenuation map (μmap), thus resulting in overcorrection for attenuation of positron emission tomography (PET) images. In this study, we developed an automated algorithm for segmentation and classification of regions containing oral contrast medium to correct for artifacts in CT-attenuation-corrected PET images using the segmented contrast correction (SCC) algorithm. Methods  The proposed algorithm consists of two steps: first, high CT number object segmentation using combined region- and boundary-based segmentation and second, object classification to bone and contrast agent using a knowledge-based nonlinear fuzzy classifier. Thereafter, the CT numbers of pixels belonging to the region classified as contrast medium are substituted with their equivalent effective bone CT numbers using the SCC algorithm. The generated CT images are then down-sampled followed by Gaussian smoothing to match the resolution of PET images. A piecewise calibration curve was then used to convert CT pixel values to linear attenuation coefficients at 511 keV. Results  The visual assessment of segmented regions performed by an experienced radiologist confirmed the accuracy of the segmentation and classification algorithms for delineation of contrast-enhanced regions in clinical CT images. The quantitative analysis of generated μmaps of 21 clinical CT colonoscopy datasets showed an overestimation ranging between 24.4% and 37.3% in the 3D-classified regions depending on their volume and the concentration of contrast medium. Two PET/CT studies known to be problematic demonstrated the applicability of the technique in clinical setting. More importantly, correction of oral contrast artifacts improved the readability and interpretation of the PET scan and showed substantial decrease of the SUV (104.3%) after correction. Conclusions  An automated segmentation algorithm for classification of irregular shapes of regions containing contrast medium was developed for wider applicability of the SCC algorithm for correction of oral contrast artifacts during the CTAC procedure. The algorithm is being refined and further validated in clinical setting.     

Application of intravenous contrast in PET/CT: does it really introduce significant attenuation correction error?

The current perception of using contrast-enhanced CT (CECT) for attenuation correction (AC) is that of caution, as it might lead to erroneously elevated (18)F-FDG uptake on the PET scan. This study evaluates in vivo whether an intravenous iodinated contrast agent produces a significant AC artifact in the level of standardized uptake value (SUV) changes in PET/CT. METHODS: Fifty-four patients referred for whole-body (WB) PET/CT scans were enrolled and subdivided into 2 groups. In part I, 26 patients had a single WB PET scan that was corrected for attenuation using noncontrast and intravenous CECT obtained before and after the emission data, respectively. The final PET images were compared for any visual and SUV maximum (SUV(max)) measurement difference. This allowed analysis of the compatibility of the scaling processes between the 2 different CTs and the PET. The SUV(max) values were obtained from ascending aorta, upper lung, femoral head, iliopsoas muscle, spleen, liver, and the site of pathology (total, 193 regions). Part II addressed whether intravenous contrast also influenced the PET emission data. For that purpose, the remaining 28 patients underwent a limited plain CT scan from lung base to lower liver edge, followed by a 1-bed PET scan of the same region and then a WB intravenous contrast CT scan in tandem with a WB PET scan. SUV(max) values were obtained at the lung base, liver, spleen, T11 or T12 vertebra, and paraspinal muscle (total, 135 regions). The data obtained from pre- and post-intravenous contrast PET scans were analyzed as in part I. RESULTS: There was no statistically significant elevation of the SUV level in the measured anatomic sites as a whole (part I: mean SUV(max) difference = 0.06, P > 0.05; Part II: mean SUV(max) difference = -0.02, P > 0.05). However, statistically significant results as a group (mean SUV(max) difference = 0.26, P < 0.05)--albeit considered to be clinically insignificant--were observed for areas of pathology in the part I study. No abnormal focal increased (18)F-FDG activity was detected as a result of the intravenous contrast in both parts of this examination. CONCLUSION: No statistically or clinically significant spuriously elevated SUV level that might potentially interfere with the diagnostic value of PET/CT was identified as a result of the application of intravenous iodinated contrast.     

Effect of MR contrast agents on quantitative accuracy of PET in combined whole-body PET/MR imaging

Purpose

Clinical PET/MR acquisition protocols entail the use of MR contrast agents (MRCA) that could potentially affect PET quantification following MR-based attenuation correction (AC). We assessed the effect of oral and intravenous (IV) MRCA on PET quantification in PET/MR imaging.

Methods

We employed two MRCA: Lumirem? (oral) and Gadovist? (IV). First, we determined their reference PET attenuation values using a PET transmission scan (ECAT-EXACT HR+, Siemens) and a CT scan (PET/CT Biograph 16 HI-REZ, Siemens). Second, we evaluated the attenuation of PET signals in the presence of MRCA. Phantoms were filled with clinically relevant concentrations of MRCA in a background of water and ¹⁸F-fluoride, and imaged using a PET/CT scanner (Biograph 16 HI-REZ, Siemens) and a PET/MR scanner (Biograph mMR, Siemens). Third, we investigated the effect of clinically relevant volumes of MRCA on MR-based AC using human pilot data: a patient study employing Gadovist? (IV) and a volunteer study employing two different oral MRCA (Lumirem? and pineapple juice). MR-based attenuation maps were calculated following Dixon-based fat–water segmentation and an external atlas-based and pattern recognition (AT&PR) algorithm.

Results

IV and oral MRCA in clinically relevant concentrations were found to have PET attenuation values similar to those of water. The phantom experiments showed that under clinical conditions IV and oral MRCA did not yield additional attenuation of PET emission signals. Patient scans showed that PET attenuation maps are not biased after the administration of IV MRCA but may be biased, however, after ingestion of iron oxide-based oral MRCA when segmentation-based AC algorithms are used. Alternative AC algorithms, such as AT&PR, or alternative oral contrast agents, such as pineapple juice, can yield unbiased attenuation maps.

Conclusion

In clinical PET/MR scenarios MRCA are not expected to lead to markedly increased attenuation of the PET emission signals. MR-based attenuation maps may be biased by oral iron oxide-based MRCA unless advanced AC algorithms are used.